Global Immunodeficiency Therapeutics Market By Therapy Type (Gene Therapy, Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem Cell Transplantation, Others); Route of Administration (Intravenous, Subcutaneous); By Disorder Type (Primary – Common Variable Immunodeficiency (CVID), Severe Combined Immunodeficiency (SCID) (Alymphocytosis), Chronic Granulomatous Disease (CGD), Others, Secondary – AIDS, Cancer, Hepatitis, Others); By Demography (Kids, Adults); By Test Type (Blood Prenatal); By End Users (Hospitals and Clinics, Specialized Clinics, Research Centers, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
In terms of revenue, the global immunodeficiency therapeutics market was valued at US$ 6,991.1 Mn in 2021, growing at an estimated CAGR of 6.9% over the forecast period. Several factors are impacting the immunity of numerous people. Right from sedentary lifestyle, excessive consumption of junk food which is less nutritive to getting infected with chronic diseases. This is helping the global immunodeficiency therapeutics market grow at the fastest rate. Weak immunity affects overall lifestyle of every individual making them more prone to various infections and diseases. The COVID-19 pandemic proved extremely beneficial for the global immunodeficiency therapeutics market. People with weaker immune system were under threat of being infected by the deadly virus. The demand for medicines and drugs that boost immunity spiked, ultimately generating huge amount of revenue for this market.
Therapy Type Outlook
On the basis of therapy type, the global immunodeficiency therapeutics market has been divided into gene therapy, immunoglobulin replacement therapy, antibiotics therapy, stem cell transplantation and others. The immunoglobulin replacement therapy is definitely the most sought-after treatment. In this therapy type, a certain type of protein that function as antibodies are injected in the body.
Route of Administration Outlook
On the basis of route of administration, the global immunodeficiency therapeutics market has been segmented into intravenous and subcutaneously. While in the intravenous way of administration, the antibodies are administered through a vein, in other way of administration, an injection is used in the layer of skin under the dermis and epidermis.
Global Immunodeficiency Therapeutics Market Revenue & Forecast, (US$ Million), 2022 – 2030
Disorder Type Outlook
On the basis of the disorder type, the global immunodeficiency therapeutics market has been segregated into primary and secondary. The primary segment is further divided into common variable immunodeficiency (CVID), severe combined immunodeficiency (SCID) (Alymphocytosis), chronic granulomatous disease (CGD) and others. On the other hand, the secondary segment is bifurcated into AIDS, cancer, hepatitis, and others. The primary segment accounts for majority of revenue generated by this market.
Demography Outlook
On the basis of demography, the global immunodeficiency therapeutics market has been categorised into kids and adults. The adults segment generates majority of revenue for this market. This is primarily because these treatments are more suitable for adults and also mostly required by them.
Test Type Outlook
On the basis of test type, the global immunodeficiency therapeutics market has been bifurcated into blood and prenatal. In order to diagnose, immunity related issues in a baby, prenatal testing is done. There are three types of prenatal testing, cell-free fetal DNA testing, chlrionic villus sampling and first-trimester ultrasound.
End Users Outlook
The end users’ segment of the global immunodeficiency therapeutics market has been divided into hospitals and clinics, specialized clinics, research centers and others. The hospitals and clinics segment account for majority of revenue generated by this market. The number of patients seeking this treatment at hospitals and clinics are on a higher side compared to other medical facilities.
Region Outlook
On the basis of region, the global immunodeficiency therapeutics market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of North America accounts for majority of revenue generated by this market. Presence of top-class medical facilities in countries like the United States and Canada drive this market’s growth rampantly. Also patients living in the region can afford this type of treatment which cost on the higher side.
Competitive Landscape
The report provides both, qualitative and quantitative research of global immunodeficiency therapeutics market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global immunodeficiency therapeutics market are listed below:
- ADMA Biologics
- Baxter
- CSL
- Grifols, S.A.
- GSK Group of Companies
- Lupin Pharmaceuticals Inc.
- Novartis AG
- Octapharma AG
- Takeda Pharmaceutical Company Limited
- X4 Pharmaceuticals, Inc
- Other Market Participants
Global Immunodeficiency Therapeutics Market
By Therapy Type
- Gene Therapy
- Immunoglobulin Replacement Therapy
- Antibiotics Therapy
- Stem Cell Transportation
- Others
By Route of Administration
- Intravenous
- Subcutaneous
By Disorder Type
- Primary
- Common Variable Immunodeficiency (CVID)
- Severe Combined Immunodeficiency (SCID) (Alymphocytosis)
- Chronic Granulomatous Disease (CGD)
- Others
- Secondary
- AIDS
- Cancer
- Hepatitis
- Others
By Demography
- Kids
- Adults
By Test Type
- Blood
- Prenatal
By End Users
- Hospitals and Clinics
- Specialized Clinics
- Research Centers
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Immunodeficiency Therapeutics Market
6.
Market
Synopsis: Immunodeficiency Therapeutics
Market
7.
Immunodeficiency
Therapeutics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Immunodeficiency Therapeutics
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Immunodeficiency Therapeutics Market
8.
Global
Immunodeficiency Therapeutics Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Immunodeficiency Therapeutics Market
Revenue (US$ Mn)
8.2. Global Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapy Type
8.2.1. Gene Therapy
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 – 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Immunoglobulin Replacement Therapy
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 – 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Antibiotics Therapy
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 – 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.2.4. Stem Cell Transportation
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 – 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 – 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 – 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 – 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 – 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 – 2030
8.2.5. Others
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 – 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 – 2030
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 – 2030
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 – 2030
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 – 2030
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Therapy Type
9.
Global
Immunodeficiency Therapeutics Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
9.2.1. Intravenous
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 – 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Subcutaneous
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 – 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Route of Administration
10. Global Immunodeficiency Therapeutics Market
Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Disorder Type
10.2.1. Primary (Definition, Market Estimation and
Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022
– 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Common Variable Immunodeficiency (CVID), Severe Combined
Immunodeficiency (SCID) (Alymphocytosis), Chronic Granulomatous Disease (CGD),
Others)
10.2.1.1.
Common
Variable Immunodeficiency (CVID)
10.2.1.2.
Severe
Combined Immunodeficiency (SCID) (Alymphocytosis)
10.2.1.3.
Chronic
Granulomatous Disease (CGD)
10.2.1.4.
Others
10.2.2. Secondary (Definition, Market Estimation and
Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022
– 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on AIDS, Cancer, Hepatitis, Others)
10.2.2.1.
AIDS
10.2.2.2.
Cancer
10.2.2.3.
Hepatitis
10.2.2.4.
Others
10.3. Key Segment for Channeling Investments
10.3.1. By Disorder Type
11. Global Immunodeficiency Therapeutics Market
Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Demography
11.2.1. Adults
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 – 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Kids
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 – 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 – 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 – 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Demography
12. Global Immunodeficiency Therapeutics Market
Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.2. Global Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.2.1. Blood
12.2.1.1.
Definition
12.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.1.3.
Market
Forecast, 2022 – 2030
12.2.1.4.
Compound
Annual Growth Rate (CAGR)
12.2.1.5.
Regional
Bifurcation
12.2.1.5.1.
North
America
12.2.1.5.1.1. Market Estimation, 2015 - 2021
12.2.1.5.1.2. Market Forecast, 2022 – 2030
12.2.1.5.2.
Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2021
12.2.1.5.2.2. Market Forecast, 2022 – 2030
12.2.1.5.3.
Asia
Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2021
12.2.1.5.3.2. Market Forecast, 2022 – 2030
12.2.1.5.4.
Middle
East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2021
12.2.1.5.4.2. Market Forecast, 2022 – 2030
12.2.1.5.5.
Latin
America
12.2.1.5.5.1. Market Estimation, 2015 - 2021
12.2.1.5.5.2. Market Forecast, 2022 – 2030
12.2.2. Prenatal
12.2.2.1.
Definition
12.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.2.3.
Market
Forecast, 2022 – 2030
12.2.2.4.
Compound
Annual Growth Rate (CAGR)
12.2.2.5.
Regional
Bifurcation
12.2.2.5.1.
North
America
12.2.2.5.1.1. Market Estimation, 2015 - 2021
12.2.2.5.1.2. Market Forecast, 2022 – 2030
12.2.2.5.2.
Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2021
12.2.2.5.2.2. Market Forecast, 2022 – 2030
12.2.2.5.3.
Asia
Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2021
12.2.2.5.3.2. Market Forecast, 2022 – 2030
12.2.2.5.4.
Middle
East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2021
12.2.2.5.4.2. Market Forecast, 2022 – 2030
12.2.2.5.5.
Latin
America
12.2.2.5.5.1. Market Estimation, 2015 - 2021
12.2.2.5.5.2. Market Forecast, 2022 – 2030
12.3. Key Segment for Channeling Investments
12.3.1. By Test Type
13. Global Immunodeficiency Therapeutics Market
Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.2. Global Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End Users
13.2.1. Hospitals and Clinics
13.2.1.1.
Definition
13.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
13.2.1.3.
Market
Forecast, 2022 – 2030
13.2.1.4.
Compound
Annual Growth Rate (CAGR)
13.2.1.5.
Regional
Bifurcation
13.2.1.5.1.
North
America
13.2.1.5.1.1. Market Estimation, 2015 - 2021
13.2.1.5.1.2. Market Forecast, 2022 – 2030
13.2.1.5.2.
Europe
13.2.1.5.2.1. Market Estimation, 2015 - 2021
13.2.1.5.2.2. Market Forecast, 2022 – 2030
13.2.1.5.3.
Asia
Pacific
13.2.1.5.3.1. Market Estimation, 2015 - 2021
13.2.1.5.3.2. Market Forecast, 2022 – 2030
13.2.1.5.4.
Middle
East and Africa
13.2.1.5.4.1. Market Estimation, 2015 - 2021
13.2.1.5.4.2. Market Forecast, 2022 – 2030
13.2.1.5.5.
Latin
America
13.2.1.5.5.1. Market Estimation, 2015 - 2021
13.2.1.5.5.2. Market Forecast, 2022 – 2030
13.2.2. Specialized Clinics
13.2.2.1.
Definition
13.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
13.2.2.3.
Market
Forecast, 2022 – 2030
13.2.2.4.
Compound
Annual Growth Rate (CAGR)
13.2.2.5.
Regional
Bifurcation
13.2.2.5.1.
North
America
13.2.2.5.1.1. Market Estimation, 2015 - 2021
13.2.2.5.1.2. Market Forecast, 2022 – 2030
13.2.2.5.2.
Europe
13.2.2.5.2.1. Market Estimation, 2015 - 2021
13.2.2.5.2.2. Market Forecast, 2022 – 2030
13.2.2.5.3.
Asia
Pacific
13.2.2.5.3.1. Market Estimation, 2015 - 2021
13.2.2.5.3.2. Market Forecast, 2022 – 2030
13.2.2.5.4.
Middle
East and Africa
13.2.2.5.4.1. Market Estimation, 2015 - 2021
13.2.2.5.4.2. Market Forecast, 2022 – 2030
13.2.2.5.5.
Latin
America
13.2.2.5.5.1. Market Estimation, 2015 - 2021
13.2.2.5.5.2. Market Forecast, 2022 – 2030
13.2.3. Research Centers
13.2.3.1.
Definition
13.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
13.2.3.3.
Market
Forecast, 2022 – 2030
13.2.3.4.
Compound
Annual Growth Rate (CAGR)
13.2.3.5.
Regional
Bifurcation
13.2.3.5.1.
North
America
13.2.3.5.1.1. Market Estimation, 2015 - 2021
13.2.3.5.1.2. Market Forecast, 2022 – 2030
13.2.3.5.2.
Europe
13.2.3.5.2.1. Market Estimation, 2015 - 2021
13.2.3.5.2.2. Market Forecast, 2022 – 2030
13.2.3.5.3.
Asia
Pacific
13.2.3.5.3.1. Market Estimation, 2015 - 2021
13.2.3.5.3.2. Market Forecast, 2022 – 2030
13.2.3.5.4.
Middle
East and Africa
13.2.3.5.4.1. Market Estimation, 2015 - 2021
13.2.3.5.4.2. Market Forecast, 2022 – 2030
13.2.3.5.5.
Latin
America
13.2.3.5.5.1. Market Estimation, 2015 - 2021
13.2.3.5.5.2. Market Forecast, 2022 – 2030
13.2.4. Others
13.2.4.1.
Definition
13.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
13.2.4.3.
Market
Forecast, 2022 – 2030
13.2.4.4.
Compound
Annual Growth Rate (CAGR)
13.2.4.5.
Regional
Bifurcation
13.2.4.5.1.
North
America
13.2.4.5.1.1. Market Estimation, 2015 - 2021
13.2.4.5.1.2. Market Forecast, 2022 – 2030
13.2.4.5.2.
Europe
13.2.4.5.2.1. Market Estimation, 2015 - 2021
13.2.4.5.2.2. Market Forecast, 2022 – 2030
13.2.4.5.3.
Asia
Pacific
13.2.4.5.3.1. Market Estimation, 2015 - 2021
13.2.4.5.3.2. Market Forecast, 2022 – 2030
13.2.4.5.4.
Middle
East and Africa
13.2.4.5.4.1. Market Estimation, 2015 - 2021
13.2.4.5.4.2. Market Forecast, 2022 – 2030
13.2.4.5.5.
Latin
America
13.2.4.5.5.1. Market Estimation, 2015 - 2021
13.2.4.5.5.2. Market Forecast, 2022 – 2030
13.3. Key Segment for Channeling Investments
13.3.1. By End Users
14. North America Immunodeficiency Therapeutics
Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. North America Immunodeficiency Therapeutics
Market Revenue (US$ Mn)
14.2. North America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Therapy Type
14.2.1. Gene Therapy
14.2.2. Immunoglobulin Replacement Therapy
14.2.3. Antibiotics Therapy
14.2.4. Stem Cell Transportation
14.2.5. Others
14.3. North America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.3.1. Intravenous
14.3.2. Subcutaneous
14.4. North America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Disorder Type
14.4.1. Primary
14.4.1.1.
Common
Variable Immunodeficiency (CVID)
14.4.1.2.
Severe
Combined Immunodeficiency (SCID) (Alymphocytosis)
14.4.1.3.
Chronic
Granulomatous Disease (CGD)
14.4.1.4.
Others
14.4.2. Secondary
14.4.2.1.
AIDS
14.4.2.2.
Cancer
14.4.2.3.
Hepatitis
14.4.2.4.
Others
14.5. North America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Demography
14.5.1. Adults
14.5.2. Kids
14.6. North America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Test Type
14.6.1. Blood
14.6.2. Prenatal
14.7. North America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.1. Hospitals and Clinics
14.7.2. Specialized Clinics
14.7.3. Research Centers
14.7.4. Others
14.8. North America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
14.8.1. U.S
14.8.1.1.
U.S Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy Type
14.8.1.1.1.
Gene
Therapy
14.8.1.1.2.
Immunoglobulin
Replacement Therapy
14.8.1.1.3.
Antibiotics
Therapy
14.8.1.1.4.
Stem
Cell Transportation
14.8.1.1.5.
Others
14.8.1.2.
U.S
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.8.1.2.1.
Intravenous
14.8.1.2.2.
Subcutaneous
14.8.1.3.
U.S
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
14.8.1.3.1.
Primary
14.8.1.3.1.1. Common Variable Immunodeficiency (CVID)
14.8.1.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
14.8.1.3.1.3. Chronic Granulomatous Disease (CGD)
14.8.1.3.1.4. Others
14.8.1.3.2.
Secondary
14.8.1.3.2.1. AIDS
14.8.1.3.2.2. Cancer
14.8.1.3.2.3. Hepatitis
14.8.1.3.2.4. Others
14.8.1.4.
U.S
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
14.8.1.4.1.
Adults
14.8.1.4.2.
Kids
14.8.1.5.
U.S
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test Type
14.8.1.5.1.
Blood
14.8.1.5.2.
Prenatal
14.8.1.6.
U.S
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
14.8.1.6.1.
Hospitals
and Clinics
14.8.1.6.2.
Specialized
Clinics
14.8.1.6.3.
Research
Centers
14.8.1.6.4.
Others
14.8.2. Canada
14.8.2.1.
Canada
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
14.8.2.1.1.
Gene
Therapy
14.8.2.1.2.
Immunoglobulin
Replacement Therapy
14.8.2.1.3.
Antibiotics
Therapy
14.8.2.1.4.
Stem
Cell Transportation
14.8.2.1.5.
Others
14.8.2.2.
Canada
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.8.2.2.1.
Intravenous
14.8.2.2.2.
Subcutaneous
14.8.2.3.
Canada Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disorder Type
14.8.2.3.1.
Primary
14.8.2.3.1.1. Common Variable Immunodeficiency (CVID)
14.8.2.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
14.8.2.3.1.3. Chronic Granulomatous Disease (CGD)
14.8.2.3.1.4. Others
14.8.2.3.2.
Secondary
14.8.2.3.2.1. AIDS
14.8.2.3.2.2. Cancer
14.8.2.3.2.3. Hepatitis
14.8.2.3.2.4. Others
14.8.2.4.
Canada
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
14.8.2.4.1.
Adults
14.8.2.4.2.
Kids
14.8.2.5.
Canada
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
14.8.2.5.1.
Blood
14.8.2.5.2.
Prenatal
14.8.2.6.
Canada
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
14.8.2.6.1.
Hospitals
and Clinics
14.8.2.6.2.
Specialized
Clinics
14.8.2.6.3.
Research
Centers
14.8.2.6.4.
Others
14.8.3. Mexico
14.8.3.1.
Mexico
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
14.8.3.1.1.
Gene
Therapy
14.8.3.1.2.
Immunoglobulin
Replacement Therapy
14.8.3.1.3.
Antibiotics
Therapy
14.8.3.1.4.
Stem
Cell Transportation
14.8.3.1.5.
Others
14.8.3.2.
Mexico
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.8.3.2.1.
Intravenous
14.8.3.2.2.
Subcutaneous
14.8.3.3.
Mexico
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
14.8.3.3.1.
Primary
14.8.3.3.1.1. Common Variable Immunodeficiency (CVID)
14.8.3.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
14.8.3.3.1.3. Chronic Granulomatous Disease (CGD)
14.8.3.3.1.4. Others
14.8.3.3.2.
Secondary
14.8.3.3.2.1. AIDS
14.8.3.3.2.2. Cancer
14.8.3.3.2.3. Hepatitis
14.8.3.3.2.4. Others
14.8.3.4.
Mexico
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
14.8.3.4.1.
Adults
14.8.3.4.2.
Kids
14.8.3.5.
Mexico
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
14.8.3.5.1.
Blood
14.8.3.5.2.
Prenatal
14.8.3.6.
Mexico
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
14.8.3.6.1.
Hospitals
and Clinics
14.8.3.6.2.
Specialized
Clinics
14.8.3.6.3.
Research
Centers
14.8.3.6.4.
Others
14.8.4. Rest of North America
14.8.4.1.
Rest of
North America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
14.8.4.1.1.
Gene
Therapy
14.8.4.1.2.
Immunoglobulin
Replacement Therapy
14.8.4.1.3.
Antibiotics
Therapy
14.8.4.1.4.
Stem
Cell Transportation
14.8.4.1.5.
Others
14.8.4.2.
Rest of
North America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.8.4.2.1.
Intravenous
14.8.4.2.2.
Subcutaneous
14.8.4.3.
Rest of
North America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Disorder Type
14.8.4.3.1.
Primary
14.8.4.3.1.1. Common Variable Immunodeficiency (CVID)
14.8.4.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
14.8.4.3.1.3. Chronic Granulomatous Disease (CGD)
14.8.4.3.1.4. Others
14.8.4.3.2.
Secondary
14.8.4.3.2.1. AIDS
14.8.4.3.2.2. Cancer
14.8.4.3.2.3. Hepatitis
14.8.4.3.2.4. Others
14.8.4.4.
Rest of
North America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Demography
14.8.4.4.1.
Adults
14.8.4.4.2.
Kids
14.8.4.5.
Rest of
North America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Test Type
14.8.4.5.1.
Blood
14.8.4.5.2.
Prenatal
14.8.4.6.
Rest of
North America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By End Users
14.8.4.6.1.
Hospitals
and Clinics
14.8.4.6.2.
Specialized
Clinics
14.8.4.6.3.
Research
Centers
14.8.4.6.4.
Others
14.9. Key Segment for Channeling Investments
14.9.1. By Country
14.9.2. By Therapy Type
14.9.3. By Route of Administration
14.9.4. By Disorder Type
14.9.5. By Demography
14.9.6. By Test Type
14.9.7. By End Users
15. Europe Immunodeficiency Therapeutics Market
Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Europe Immunodeficiency Therapeutics Market
Revenue (US$ Mn)
15.2. Europe Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapy Type
15.2.1. Gene Therapy
15.2.2. Immunoglobulin Replacement Therapy
15.2.3. Antibiotics Therapy
15.2.4. Stem Cell Transportation
15.2.5. Others
15.3. Europe Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.3.1. Intravenous
15.3.2. Subcutaneous
15.4. Europe Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Disorder Type
15.4.1. Primary
15.4.1.1.
Common
Variable Immunodeficiency (CVID)
15.4.1.2.
Severe
Combined Immunodeficiency (SCID) (Alymphocytosis)
15.4.1.3.
Chronic
Granulomatous Disease (CGD)
15.4.1.4.
Others
15.4.2. Secondary
15.4.2.1.
AIDS
15.4.2.2.
Cancer
15.4.2.3.
Hepatitis
15.4.2.4.
Others
15.5. Europe Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Demography
15.5.1. Adults
15.5.2. Kids
15.6. Europe Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Test Type
15.6.1. Blood
15.6.2. Prenatal
15.7. Europe Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End Users
15.7.1. Hospitals and Clinics
15.7.2. Specialized Clinics
15.7.3. Research Centers
15.7.4. Others
15.8. Europe Immunodeficiency Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
15.8.1. France
15.8.1.1.
France
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
15.8.1.1.1.
Gene
Therapy
15.8.1.1.2.
Immunoglobulin
Replacement Therapy
15.8.1.1.3.
Antibiotics
Therapy
15.8.1.1.4.
Stem
Cell Transportation
15.8.1.1.5.
Others
15.8.1.2.
France
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.8.1.2.1.
Intravenous
15.8.1.2.2.
Subcutaneous
15.8.1.3.
France
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
15.8.1.3.1.
Primary
15.8.1.3.1.1. Common Variable Immunodeficiency (CVID)
15.8.1.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
15.8.1.3.1.3. Chronic Granulomatous Disease (CGD)
15.8.1.3.1.4. Others
15.8.1.3.2.
Secondary
15.8.1.3.2.1. AIDS
15.8.1.3.2.2. Cancer
15.8.1.3.2.3. Hepatitis
15.8.1.3.2.4. Others
15.8.1.4.
France
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
15.8.1.4.1.
Adults
15.8.1.4.2.
Kids
15.8.1.5.
France
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
15.8.1.5.1.
Blood
15.8.1.5.2.
Prenatal
15.8.1.6.
France Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By End Users
15.8.1.6.1.
Hospitals
and Clinics
15.8.1.6.2.
Specialized
Clinics
15.8.1.6.3.
Research
Centers
15.8.1.6.4.
Others
15.8.2. The UK
15.8.2.1.
The UK
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
15.8.2.1.1.
Gene Therapy
15.8.2.1.2.
Immunoglobulin
Replacement Therapy
15.8.2.1.3.
Antibiotics
Therapy
15.8.2.1.4.
Stem
Cell Transportation
15.8.2.1.5.
Others
15.8.2.2.
The UK
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.8.2.2.1.
Intravenous
15.8.2.2.2.
Subcutaneous
15.8.2.3.
The UK
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
15.8.2.3.1.
Primary
15.8.2.3.1.1. Common Variable Immunodeficiency (CVID)
15.8.2.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
15.8.2.3.1.3. Chronic Granulomatous Disease (CGD)
15.8.2.3.1.4. Others
15.8.2.3.2.
Secondary
15.8.2.3.2.1. AIDS
15.8.2.3.2.2. Cancer
15.8.2.3.2.3. Hepatitis
15.8.2.3.2.4. Others
15.8.2.4.
The UK
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
15.8.2.4.1.
Adults
15.8.2.4.2.
Kids
15.8.2.5.
The UK
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
15.8.2.5.1.
Blood
15.8.2.5.2.
Prenatal
15.8.2.6.
The UK
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
15.8.2.6.1.
Hospitals
and Clinics
15.8.2.6.2.
Specialized
Clinics
15.8.2.6.3.
Research
Centers
15.8.2.6.4.
Others
15.8.3. Spain
15.8.3.1.
Spain
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
15.8.3.1.1.
Gene
Therapy
15.8.3.1.2.
Immunoglobulin
Replacement Therapy
15.8.3.1.3.
Antibiotics
Therapy
15.8.3.1.4.
Stem
Cell Transportation
15.8.3.1.5.
Others
15.8.3.2.
Spain
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.8.3.2.1.
Intravenous
15.8.3.2.2.
Subcutaneous
15.8.3.3.
Spain
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
15.8.3.3.1.
Primary
15.8.3.3.1.1. Common Variable Immunodeficiency (CVID)
15.8.3.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
15.8.3.3.1.3. Chronic Granulomatous Disease (CGD)
15.8.3.3.1.4. Others
15.8.3.3.2.
Secondary
15.8.3.3.2.1. AIDS
15.8.3.3.2.2. Cancer
15.8.3.3.2.3. Hepatitis
15.8.3.3.2.4. Others
15.8.3.4.
Spain
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
15.8.3.4.1.
Adults
15.8.3.4.2.
Kids
15.8.3.5.
Spain
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
15.8.3.5.1.
Blood
15.8.3.5.2.
Prenatal
15.8.3.6.
Spain
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
15.8.3.6.1.
Hospitals
and Clinics
15.8.3.6.2.
Specialized
Clinics
15.8.3.6.3.
Research
Centers
15.8.3.6.4.
Others
15.8.4. Germany
15.8.4.1.
Germany
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
15.8.4.1.1.
Gene
Therapy
15.8.4.1.2.
Immunoglobulin
Replacement Therapy
15.8.4.1.3.
Antibiotics
Therapy
15.8.4.1.4.
Stem
Cell Transportation
15.8.4.1.5.
Others
15.8.4.2.
Germany
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.8.4.2.1.
Intravenous
15.8.4.2.2.
Subcutaneous
15.8.4.3.
Germany
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
15.8.4.3.1.
Primary
15.8.4.3.1.1. Common Variable Immunodeficiency (CVID)
15.8.4.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
15.8.4.3.1.3. Chronic Granulomatous Disease (CGD)
15.8.4.3.1.4. Others
15.8.4.3.2.
Secondary
15.8.4.3.2.1. AIDS
15.8.4.3.2.2. Cancer
15.8.4.3.2.3. Hepatitis
15.8.4.3.2.4. Others
15.8.4.4.
Germany
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
15.8.4.4.1.
Adults
15.8.4.4.2.
Kids
15.8.4.5.
Germany Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test Type
15.8.4.5.1.
Blood
15.8.4.5.2.
Prenatal
15.8.4.6.
Germany
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
15.8.4.6.1.
Hospitals
and Clinics
15.8.4.6.2.
Specialized
Clinics
15.8.4.6.3.
Research
Centers
15.8.4.6.4.
Others
15.8.5. Italy
15.8.5.1.
Italy
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
15.8.5.1.1.
Gene
Therapy
15.8.5.1.2.
Immunoglobulin
Replacement Therapy
15.8.5.1.3.
Antibiotics
Therapy
15.8.5.1.4.
Stem
Cell Transportation
15.8.5.1.5.
Others
15.8.5.2.
Italy
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.8.5.2.1.
Intravenous
15.8.5.2.2.
Subcutaneous
15.8.5.3.
Italy
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
15.8.5.3.1.
Primary
15.8.5.3.1.1. Common Variable Immunodeficiency (CVID)
15.8.5.3.1.2. Severe Combined Immunodeficiency (SCID) (Alymphocytosis)
15.8.5.3.1.3. Chronic Granulomatous Disease (CGD)
15.8.5.3.1.4. Others
15.8.5.3.2.
Secondary
15.8.5.3.2.1. AIDS
15.8.5.3.2.2. Cancer
15.8.5.3.2.3. Hepatitis
15.8.5.3.2.4. Others
15.8.5.4.
Italy
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
15.8.5.4.1.
Adults
15.8.5.4.2.
Kids
15.8.5.5.
Italy
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
15.8.5.5.1.
Blood
15.8.5.5.2.
Prenatal
15.8.5.6.
Italy
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
15.8.5.6.1.
Hospitals
and Clinics
15.8.5.6.2.
Specialized
Clinics
15.8.5.6.3.
Research
Centers
15.8.5.6.4.
Others
15.8.6. Nordic Countries
15.8.6.1.
Nordic
Countries Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Therapy Type
15.8.6.1.1.
Gene
Therapy
15.8.6.1.2.
Immunoglobulin
Replacement Therapy
15.8.6.1.3.
Antibiotics
Therapy
15.8.6.1.4.
Stem
Cell Transportation
15.8.6.1.5.
Others
15.8.6.2.
Nordic
Countries Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.8.6.2.1.
Intravenous
15.8.6.2.2.
Subcutaneous
15.8.6.3.
Nordic
Countries Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Disorder Type
15.8.6.3.1.
Primary
15.8.6.3.1.1. Common Variable Immunodeficiency (CVID)
15.8.6.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
15.8.6.3.1.3. Chronic Granulomatous Disease (CGD)
15.8.6.3.1.4. Others
15.8.6.3.2.
Secondary
15.8.6.3.2.1. AIDS
15.8.6.3.2.2. Cancer
15.8.6.3.2.3. Hepatitis
15.8.6.3.2.4. Others
15.8.6.4.
Nordic
Countries Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Demography
15.8.6.4.1.
Adults
15.8.6.4.2.
Kids
15.8.6.5.
Nordic
Countries Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Test Type
15.8.6.5.1.
Blood
15.8.6.5.2.
Prenatal
15.8.6.6.
Nordic
Countries Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts,
By End Users
15.8.6.6.1.
Hospitals
and Clinics
15.8.6.6.2.
Specialized
Clinics
15.8.6.6.3.
Research
Centers
15.8.6.6.4.
Others
15.8.6.7.
Nordic
Countries Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Country
15.8.6.7.1.
Denmark
15.8.6.7.2.
Finland
15.8.6.7.3.
Iceland
15.8.6.7.4.
Sweden
15.8.6.7.5.
Norway
15.8.7. Benelux Union
15.8.7.1.
Benelux
Union Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
15.8.7.1.1.
Gene
Therapy
15.8.7.1.2.
Immunoglobulin
Replacement Therapy
15.8.7.1.3.
Antibiotics
Therapy
15.8.7.1.4.
Stem
Cell Transportation
15.8.7.1.5.
Others
15.8.7.2.
Benelux
Union Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.8.7.2.1.
Intravenous
15.8.7.2.2.
Subcutaneous
15.8.7.3.
Benelux
Union Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
15.8.7.3.1.
Primary
15.8.7.3.1.1. Common Variable Immunodeficiency (CVID)
15.8.7.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
15.8.7.3.1.3. Chronic Granulomatous Disease (CGD)
15.8.7.3.1.4. Others
15.8.7.3.2.
Secondary
15.8.7.3.2.1. AIDS
15.8.7.3.2.2. Cancer
15.8.7.3.2.3. Hepatitis
15.8.7.3.2.4. Others
15.8.7.4.
Benelux
Union Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
15.8.7.4.1.
Adults
15.8.7.4.2.
Kids
15.8.7.5.
Benelux
Union Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Test Type
15.8.7.5.1.
Blood
15.8.7.5.2.
Prenatal
15.8.7.6.
Benelux
Union Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End Users
15.8.7.6.1.
Hospitals
and Clinics
15.8.7.6.2.
Specialized
Clinics
15.8.7.6.3.
Research
Centers
15.8.7.6.4.
Others
15.8.7.7.
Benelux
Union Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Country
15.8.7.7.1.
Belgium
15.8.7.7.2.
The
Netherlands
15.8.7.7.3.
Luxembourg
15.8.8. Rest of Europe
15.8.8.1.
Rest of
Europe Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
15.8.8.1.1.
Gene
Therapy
15.8.8.1.2.
Immunoglobulin
Replacement Therapy
15.8.8.1.3.
Antibiotics
Therapy
15.8.8.1.4.
Stem
Cell Transportation
15.8.8.1.5.
Others
15.8.8.2.
Rest of
Europe Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.8.8.2.1.
Intravenous
15.8.8.2.2.
Subcutaneous
15.8.8.3.
Rest of
Europe Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
15.8.8.3.1.
Primary
15.8.8.3.1.1. Common Variable Immunodeficiency (CVID)
15.8.8.3.1.2. Severe Combined Immunodeficiency (SCID) (Alymphocytosis)
15.8.8.3.1.3. Chronic Granulomatous Disease (CGD)
15.8.8.3.1.4. Others
15.8.8.3.2.
Secondary
15.8.8.3.2.1. AIDS
15.8.8.3.2.2. Cancer
15.8.8.3.2.3. Hepatitis
15.8.8.3.2.4. Others
15.8.8.4.
Rest of
Europe Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
15.8.8.4.1.
Adults
15.8.8.4.2.
Kids
15.8.8.5.
Rest of
Europe Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Test Type
15.8.8.5.1.
Blood
15.8.8.5.2.
Prenatal
15.8.8.6.
Rest of
Europe Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End Users
15.8.8.6.1.
Hospitals
and Clinics
15.8.8.6.2.
Specialized
Clinics
15.8.8.6.3.
Research
Centers
15.8.8.6.4.
Others
15.9. Key Segment for Channeling Investments
15.9.1. By Country
15.9.2. By Therapy Type
15.9.3. By Route of Administration
15.9.4. By Disorder Type
15.9.5. By Demography
15.9.6. By Test Type
15.9.7. By End Users
16. Asia Pacific Immunodeficiency Therapeutics
Market Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Asia Pacific Immunodeficiency Therapeutics
Market Revenue (US$ Mn)
16.2. Asia Pacific Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Therapy Type
16.2.1. Gene Therapy
16.2.2. Immunoglobulin Replacement Therapy
16.2.3. Antibiotics Therapy
16.2.4. Stem Cell Transportation
16.2.5. Others
16.3. Asia Pacific Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.3.1. Intravenous
16.3.2. Subcutaneous
16.4. Asia Pacific Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Disorder Type
16.4.1. Primary
16.4.1.1.
Common
Variable Immunodeficiency (CVID)
16.4.1.2.
Severe
Combined Immunodeficiency (SCID) (Alymphocytosis)
16.4.1.3.
Chronic
Granulomatous Disease (CGD)
16.4.1.4.
Others
16.4.2. Secondary
16.4.2.1.
AIDS
16.4.2.2.
Cancer
16.4.2.3.
Hepatitis
16.4.2.4.
Others
16.5. Asia Pacific Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Demography
16.5.1. Adults
16.5.2. Kids
16.6. Asia Pacific Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Test Type
16.6.1. Blood
16.6.2. Prenatal
16.7. Asia Pacific Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.1. Hospitals and Clinics
16.7.2. Specialized Clinics
16.7.3. Research Centers
16.7.4. Others
16.8. Asia Pacific Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
16.8.1. China
16.8.1.1.
China
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
16.8.1.1.1.
Gene
Therapy
16.8.1.1.2.
Immunoglobulin
Replacement Therapy
16.8.1.1.3.
Antibiotics
Therapy
16.8.1.1.4.
Stem
Cell Transportation
16.8.1.1.5.
Others
16.8.1.2.
China
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.8.1.2.1.
Intravenous
16.8.1.2.2.
Subcutaneous
16.8.1.3.
China
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
16.8.1.3.1.
Primary
16.8.1.3.1.1. Common Variable Immunodeficiency (CVID)
16.8.1.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
16.8.1.3.1.3. Chronic Granulomatous Disease (CGD)
16.8.1.3.1.4. Others
16.8.1.3.2.
Secondary
16.8.1.3.2.1. AIDS
16.8.1.3.2.2. Cancer
16.8.1.3.2.3. Hepatitis
16.8.1.3.2.4. Others
16.8.1.4.
China
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
16.8.1.4.1.
Adults
16.8.1.4.2.
Kids
16.8.1.5.
China
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
16.8.1.5.1.
Blood
16.8.1.5.2.
Prenatal
16.8.1.6.
China
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
16.8.1.6.1.
Hospitals
and Clinics
16.8.1.6.2.
Specialized
Clinics
16.8.1.6.3.
Research
Centers
16.8.1.6.4.
Others
16.8.2. Japan
16.8.2.1.
Japan
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
16.8.2.1.1.
Gene
Therapy
16.8.2.1.2.
Immunoglobulin
Replacement Therapy
16.8.2.1.3.
Antibiotics
Therapy
16.8.2.1.4.
Stem
Cell Transportation
16.8.2.1.5.
Others
16.8.2.2.
Japan Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.8.2.2.1.
Intravenous
16.8.2.2.2.
Subcutaneous
16.8.2.3.
Japan
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
16.8.2.3.1.
Primary
16.8.2.3.1.1. Common Variable Immunodeficiency (CVID)
16.8.2.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
16.8.2.3.1.3. Chronic Granulomatous Disease (CGD)
16.8.2.3.1.4. Others
16.8.2.3.2.
Secondary
16.8.2.3.2.1. AIDS
16.8.2.3.2.2. Cancer
16.8.2.3.2.3. Hepatitis
16.8.2.3.2.4. Others
16.8.2.4.
Japan
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
16.8.2.4.1.
Adults
16.8.2.4.2.
Kids
16.8.2.5.
Japan Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test Type
16.8.2.5.1.
Blood
16.8.2.5.2.
Prenatal
16.8.2.6.
Japan
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
16.8.2.6.1.
Hospitals
and Clinics
16.8.2.6.2.
Specialized
Clinics
16.8.2.6.3.
Research
Centers
16.8.2.6.4.
Others
16.8.3. India
16.8.3.1.
India
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
16.8.3.1.1.
Gene
Therapy
16.8.3.1.2.
Immunoglobulin
Replacement Therapy
16.8.3.1.3.
Antibiotics
Therapy
16.8.3.1.4.
Stem
Cell Transportation
16.8.3.1.5.
Others
16.8.3.2.
India
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.8.3.2.1.
Intravenous
16.8.3.2.2.
Subcutaneous
16.8.3.3.
India
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
16.8.3.3.1.
Primary
16.8.3.3.1.1. Common Variable Immunodeficiency (CVID)
16.8.3.3.1.2. Severe Combined Immunodeficiency (SCID) (Alymphocytosis)
16.8.3.3.1.3. Chronic Granulomatous Disease (CGD)
16.8.3.3.1.4. Others
16.8.3.3.2.
Secondary
16.8.3.3.2.1. AIDS
16.8.3.3.2.2. Cancer
16.8.3.3.2.3. Hepatitis
16.8.3.3.2.4. Others
16.8.3.4.
India
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
16.8.3.4.1.
Adults
16.8.3.4.2.
Kids
16.8.3.5.
India
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
16.8.3.5.1.
Blood
16.8.3.5.2.
Prenatal
16.8.3.6.
India
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
16.8.3.6.1.
Hospitals
and Clinics
16.8.3.6.2.
Specialized
Clinics
16.8.3.6.3.
Research
Centers
16.8.3.6.4.
Others
16.8.4. New Zealand
16.8.4.1.
New
Zealand Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
16.8.4.1.1.
Gene
Therapy
16.8.4.1.2.
Immunoglobulin
Replacement Therapy
16.8.4.1.3.
Antibiotics
Therapy
16.8.4.1.4.
Stem
Cell Transportation
16.8.4.1.5.
Others
16.8.4.2.
New
Zealand Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.8.4.2.1.
Intravenous
16.8.4.2.2.
Subcutaneous
16.8.4.3.
New
Zealand Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
16.8.4.3.1.
Primary
16.8.4.3.1.1. Common Variable Immunodeficiency (CVID)
16.8.4.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
16.8.4.3.1.3. Chronic Granulomatous Disease (CGD)
16.8.4.3.1.4. Others
16.8.4.3.2.
Secondary
16.8.4.3.2.1. AIDS
16.8.4.3.2.2. Cancer
16.8.4.3.2.3. Hepatitis
16.8.4.3.2.4. Others
16.8.4.4.
New
Zealand Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
16.8.4.4.1.
Adults
16.8.4.4.2.
Kids
16.8.4.5.
New
Zealand Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Test Type
16.8.4.5.1.
Blood
16.8.4.5.2.
Prenatal
16.8.4.6.
New
Zealand Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End Users
16.8.4.6.1.
Hospitals
and Clinics
16.8.4.6.2.
Specialized
Clinics
16.8.4.6.3.
Research
Centers
16.8.4.6.4.
Others
16.8.5. Australia
16.8.5.1.
Australia
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
16.8.5.1.1.
Gene
Therapy
16.8.5.1.2.
Immunoglobulin
Replacement Therapy
16.8.5.1.3.
Antibiotics
Therapy
16.8.5.1.4.
Stem
Cell Transportation
16.8.5.1.5.
Others
16.8.5.2.
Australia
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.8.5.2.1.
Intravenous
16.8.5.2.2.
Subcutaneous
16.8.5.3.
Australia
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
16.8.5.3.1.
Primary
16.8.5.3.1.1. Common Variable Immunodeficiency (CVID)
16.8.5.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
16.8.5.3.1.3. Chronic Granulomatous Disease (CGD)
16.8.5.3.1.4. Others
16.8.5.3.2.
Secondary
16.8.5.3.2.1. AIDS
16.8.5.3.2.2. Cancer
16.8.5.3.2.3. Hepatitis
16.8.5.3.2.4. Others
16.8.5.4.
Australia
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
16.8.5.4.1.
Adults
16.8.5.4.2.
Kids
16.8.5.5.
Australia
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
16.8.5.5.1.
Blood
16.8.5.5.2.
Prenatal
16.8.5.6.
Australia
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
16.8.5.6.1.
Hospitals
and Clinics
16.8.5.6.2.
Specialized
Clinics
16.8.5.6.3.
Research
Centers
16.8.5.6.4.
Others
16.8.6. South Korea
16.8.6.1.
South
Korea Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
16.8.6.1.1.
Gene
Therapy
16.8.6.1.2.
Immunoglobulin
Replacement Therapy
16.8.6.1.3.
Antibiotics
Therapy
16.8.6.1.4.
Stem
Cell Transportation
16.8.6.1.5.
Others
16.8.6.2.
South
Korea Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.8.6.2.1.
Intravenous
16.8.6.2.2.
Subcutaneous
16.8.6.3.
South
Korea Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
16.8.6.3.1.
Primary
16.8.6.3.1.1. Common Variable Immunodeficiency (CVID)
16.8.6.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
16.8.6.3.1.3. Chronic Granulomatous Disease (CGD)
16.8.6.3.1.4. Others
16.8.6.3.2.
Secondary
16.8.6.3.2.1. AIDS
16.8.6.3.2.2. Cancer
16.8.6.3.2.3. Hepatitis
16.8.6.3.2.4. Others
16.8.6.4.
South
Korea Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
16.8.6.4.1.
Adults
16.8.6.4.2.
Kids
16.8.6.5.
South
Korea Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Test Type
16.8.6.5.1.
Blood
16.8.6.5.2.
Prenatal
16.8.6.6.
South
Korea Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End Users
16.8.6.6.1.
Hospitals
and Clinics
16.8.6.6.2.
Specialized
Clinics
16.8.6.6.3.
Research
Centers
16.8.6.6.4.
Others
16.8.7. Southeast Asia
16.8.7.1.
Southeast
Asia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
16.8.7.1.1.
Gene
Therapy
16.8.7.1.2.
Immunoglobulin
Replacement Therapy
16.8.7.1.3.
Antibiotics
Therapy
16.8.7.1.4.
Stem
Cell Transportation
16.8.7.1.5.
Others
16.8.7.2.
Southeast
Asia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.8.7.2.1.
Intravenous
16.8.7.2.2.
Subcutaneous
16.8.7.3.
Southeast
Asia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
16.8.7.3.1.
Primary
16.8.7.3.1.1. Common Variable Immunodeficiency (CVID)
16.8.7.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
16.8.7.3.1.3. Chronic Granulomatous Disease (CGD)
16.8.7.3.1.4. Others
16.8.7.3.2.
Secondary
16.8.7.3.2.1. AIDS
16.8.7.3.2.2. Cancer
16.8.7.3.2.3. Hepatitis
16.8.7.3.2.4. Others
16.8.7.4.
Southeast
Asia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
16.8.7.4.1.
Adults
16.8.7.4.2.
Kids
16.8.7.5.
Southeast
Asia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Test Type
16.8.7.5.1.
Blood
16.8.7.5.2.
Prenatal
16.8.7.6.
Southeast
Asia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End Users
16.8.7.6.1.
Hospitals
and Clinics
16.8.7.6.2.
Specialized
Clinics
16.8.7.6.3.
Research
Centers
16.8.7.6.4.
Others
16.8.7.7.
Southeast
Asia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Country
16.8.7.7.1.
Indonesia
16.8.7.7.2.
Thailand
16.8.7.7.3.
Malaysia
16.8.7.7.4.
Singapore
16.8.7.7.5.
Rest of
Southeast Asia
16.8.8. Rest of Asia Pacific
16.8.8.1.
Rest of
Asia Pacific Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
16.8.8.1.1.
Gene
Therapy
16.8.8.1.2.
Immunoglobulin
Replacement Therapy
16.8.8.1.3.
Antibiotics
Therapy
16.8.8.1.4.
Stem Cell
Transportation
16.8.8.1.5.
Others
16.8.8.2.
Rest of
Asia Pacific Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.8.8.2.1.
Intravenous
16.8.8.2.2.
Subcutaneous
16.8.8.3.
Rest of
Asia Pacific Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Disorder Type
16.8.8.3.1.
Primary
16.8.8.3.1.1. Common Variable Immunodeficiency (CVID)
16.8.8.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
16.8.8.3.1.3. Chronic Granulomatous Disease (CGD)
16.8.8.3.1.4. Others
16.8.8.3.2.
Secondary
16.8.8.3.2.1. AIDS
16.8.8.3.2.2. Cancer
16.8.8.3.2.3. Hepatitis
16.8.8.3.2.4. Others
16.8.8.4.
Rest of
Asia Pacific Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Demography
16.8.8.4.1.
Adults
16.8.8.4.2.
Kids
16.8.8.5.
Rest of
Asia Pacific Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Test Type
16.8.8.5.1.
Blood
16.8.8.5.2.
Prenatal
16.8.8.6.
Rest of
Asia Pacific Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By End Users
16.8.8.6.1.
Hospitals
and Clinics
16.8.8.6.2.
Specialized
Clinics
16.8.8.6.3.
Research
Centers
16.8.8.6.4.
Others
16.9. Key Segment for Channeling Investments
16.9.1. By Country
16.9.2. By Therapy Type
16.9.3. By Route of Administration
16.9.4. By Disorder Type
16.9.5. By Demography
16.9.6. By Test Type
16.9.7. By End Users
17. Middle East and Africa Immunodeficiency
Therapeutics Market Analysis and Forecasts, 2022 – 2030
17.1. Overview
17.1.1. Middle East and Africa Immunodeficiency
Therapeutics Market Revenue (US$ Mn)
17.2. Middle East and Africa Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy Type
17.2.1. Gene Therapy
17.2.2. Immunoglobulin Replacement Therapy
17.2.3. Antibiotics Therapy
17.2.4. Stem Cell Transportation
17.2.5. Others
17.3. Middle East and Africa Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.3.1. Intravenous
17.3.2. Subcutaneous
17.4. Middle East and Africa Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disorder Type
17.4.1. Primary
17.4.1.1.
Common
Variable Immunodeficiency (CVID)
17.4.1.2.
Severe
Combined Immunodeficiency (SCID) (Alymphocytosis)
17.4.1.3.
Chronic
Granulomatous Disease (CGD)
17.4.1.4.
Others
17.4.2. Secondary
17.4.2.1.
AIDS
17.4.2.2.
Cancer
17.4.2.3.
Hepatitis
17.4.2.4.
Others
17.5. Middle East and Africa Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Demography
17.5.1. Adults
17.5.2. Kids
17.6. Middle East and Africa Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test Type
17.6.1. Blood
17.6.2. Prenatal
17.7. Middle East and Africa Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By End Users
17.7.1. Hospitals and Clinics
17.7.2. Specialized Clinics
17.7.3. Research Centers
17.7.4. Others
17.8. Middle East and Africa Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
17.8.1. Saudi Arabia
17.8.1.1.
Saudi
Arabia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
17.8.1.1.1.
Gene
Therapy
17.8.1.1.2.
Immunoglobulin
Replacement Therapy
17.8.1.1.3.
Antibiotics
Therapy
17.8.1.1.4.
Stem
Cell Transportation
17.8.1.1.5.
Others
17.8.1.2.
Saudi
Arabia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
17.8.1.2.1.
Intravenous
17.8.1.2.2.
Subcutaneous
17.8.1.3.
Saudi
Arabia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
17.8.1.3.1.
Primary
17.8.1.3.1.1. Common Variable Immunodeficiency (CVID)
17.8.1.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
17.8.1.3.1.3. Chronic Granulomatous Disease (CGD)
17.8.1.3.1.4. Others
17.8.1.3.2.
Secondary
17.8.1.3.2.1. AIDS
17.8.1.3.2.2. Cancer
17.8.1.3.2.3. Hepatitis
17.8.1.3.2.4. Others
17.8.1.4.
Saudi
Arabia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
17.8.1.4.1.
Adults
17.8.1.4.2.
Kids
17.8.1.5.
Saudi
Arabia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Test Type
17.8.1.5.1.
Blood
17.8.1.5.2.
Prenatal
17.8.1.6.
Saudi
Arabia Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End Users
17.8.1.6.1.
Hospitals
and Clinics
17.8.1.6.2.
Specialized
Clinics
17.8.1.6.3.
Research
Centers
17.8.1.6.4.
Others
17.8.2. UAE
17.8.2.1.
UAE
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
17.8.2.1.1.
Gene
Therapy
17.8.2.1.2.
Immunoglobulin
Replacement Therapy
17.8.2.1.3.
Antibiotics
Therapy
17.8.2.1.4.
Stem
Cell Transportation
17.8.2.1.5.
Others
17.8.2.2.
UAE Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.8.2.2.1.
Intravenous
17.8.2.2.2.
Subcutaneous
17.8.2.3.
UAE
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
17.8.2.3.1.
Primary
17.8.2.3.1.1. Common Variable Immunodeficiency (CVID)
17.8.2.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
17.8.2.3.1.3. Chronic Granulomatous Disease (CGD)
17.8.2.3.1.4. Others
17.8.2.3.2.
Secondary
17.8.2.3.2.1. AIDS
17.8.2.3.2.2. Cancer
17.8.2.3.2.3. Hepatitis
17.8.2.3.2.4. Others
17.8.2.4.
UAE
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
17.8.2.4.1.
Adults
17.8.2.4.2.
Kids
17.8.2.5.
UAE
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
17.8.2.5.1.
Blood
17.8.2.5.2.
Prenatal
17.8.2.6.
UAE
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
17.8.2.6.1.
Hospitals
and Clinics
17.8.2.6.2.
Specialized
Clinics
17.8.2.6.3.
Research
Centers
17.8.2.6.4.
Others
17.8.3. Egypt
17.8.3.1.
Egypt Immunodeficiency
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy Type
17.8.3.1.1.
Gene
Therapy
17.8.3.1.2.
Immunoglobulin
Replacement Therapy
17.8.3.1.3.
Antibiotics
Therapy
17.8.3.1.4.
Stem
Cell Transportation
17.8.3.1.5.
Others
17.8.3.2.
Egypt
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
17.8.3.2.1.
Intravenous
17.8.3.2.2.
Subcutaneous
17.8.3.3.
Egypt
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
17.8.3.3.1.
Primary
17.8.3.3.1.1. Common Variable Immunodeficiency (CVID)
17.8.3.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
17.8.3.3.1.3. Chronic Granulomatous Disease (CGD)
17.8.3.3.1.4. Others
17.8.3.3.2.
Secondary
17.8.3.3.2.1. AIDS
17.8.3.3.2.2. Cancer
17.8.3.3.2.3. Hepatitis
17.8.3.3.2.4. Others
17.8.3.4.
Egypt
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
17.8.3.4.1.
Adults
17.8.3.4.2.
Kids
17.8.3.5.
Egypt
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
17.8.3.5.1.
Blood
17.8.3.5.2.
Prenatal
17.8.3.6.
Egypt
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
17.8.3.6.1.
Hospitals
and Clinics
17.8.3.6.2.
Specialized
Clinics
17.8.3.6.3.
Research
Centers
17.8.3.6.4.
Others
17.8.4. Kuwait
17.8.4.1.
Kuwait
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
17.8.4.1.1.
Gene
Therapy
17.8.4.1.2.
Immunoglobulin
Replacement Therapy
17.8.4.1.3.
Antibiotics
Therapy
17.8.4.1.4.
Stem
Cell Transportation
17.8.4.1.5.
Others
17.8.4.2.
Kuwait
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
17.8.4.2.1.
Intravenous
17.8.4.2.2.
Subcutaneous
17.8.4.3.
Kuwait
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
17.8.4.3.1.
Primary
17.8.4.3.1.1. Common Variable Immunodeficiency (CVID)
17.8.4.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
17.8.4.3.1.3. Chronic Granulomatous Disease (CGD)
17.8.4.3.1.4. Others
17.8.4.3.2.
Secondary
17.8.4.3.2.1. AIDS
17.8.4.3.2.2. Cancer
17.8.4.3.2.3. Hepatitis
17.8.4.3.2.4. Others
17.8.4.4.
Kuwait
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
17.8.4.4.1.
Adults
17.8.4.4.2.
Kids
17.8.4.5.
Kuwait
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
17.8.4.5.1.
Blood
17.8.4.5.2.
Prenatal
17.8.4.6.
Kuwait
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
17.8.4.6.1.
Hospitals
and Clinics
17.8.4.6.2.
Specialized
Clinics
17.8.4.6.3.
Research
Centers
17.8.4.6.4.
Others
17.8.5. South Africa
17.8.5.1.
South
Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
17.8.5.1.1.
Gene
Therapy
17.8.5.1.2.
Immunoglobulin
Replacement Therapy
17.8.5.1.3.
Antibiotics
Therapy
17.8.5.1.4.
Stem
Cell Transportation
17.8.5.1.5.
Others
17.8.5.2.
South
Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
17.8.5.2.1.
Intravenous
17.8.5.2.2.
Subcutaneous
17.8.5.3.
South
Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
17.8.5.3.1.
Primary
17.8.5.3.1.1. Common Variable Immunodeficiency (CVID)
17.8.5.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
17.8.5.3.1.3. Chronic Granulomatous Disease (CGD)
17.8.5.3.1.4. Others
17.8.5.3.2.
Secondary
17.8.5.3.2.1. AIDS
17.8.5.3.2.2. Cancer
17.8.5.3.2.3. Hepatitis
17.8.5.3.2.4. Others
17.8.5.4.
South
Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
17.8.5.4.1.
Adults
17.8.5.4.2.
Kids
17.8.5.5.
South
Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Test Type
17.8.5.5.1.
Blood
17.8.5.5.2.
Prenatal
17.8.5.6.
South
Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End Users
17.8.5.6.1.
Hospitals
and Clinics
17.8.5.6.2.
Specialized
Clinics
17.8.5.6.3.
Research
Centers
17.8.5.6.4.
Others
17.8.6. Rest of Middle East & Africa
17.8.6.1.
Rest of
Middle East & Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Therapy Type
17.8.6.1.1.
Gene
Therapy
17.8.6.1.2.
Immunoglobulin
Replacement Therapy
17.8.6.1.3.
Antibiotics
Therapy
17.8.6.1.4.
Stem
Cell Transportation
17.8.6.1.5.
Others
17.8.6.2.
Rest of
Middle East & Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
17.8.6.2.1.
Intravenous
17.8.6.2.2.
Subcutaneous
17.8.6.3.
Rest of
Middle East & Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Disorder Type
17.8.6.3.1.
Primary
17.8.6.3.1.1. Common Variable Immunodeficiency (CVID)
17.8.6.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
17.8.6.3.1.3. Chronic Granulomatous Disease (CGD)
17.8.6.3.1.4. Others
17.8.6.3.2.
Secondary
17.8.6.3.2.1. AIDS
17.8.6.3.2.2. Cancer
17.8.6.3.2.3. Hepatitis
17.8.6.3.2.4. Others
17.8.6.4.
Rest of
Middle East & Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Demography
17.8.6.4.1.
Adults
17.8.6.4.2.
Kids
17.8.6.5.
Rest of
Middle East & Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Test Type
17.8.6.5.1.
Blood
17.8.6.5.2.
Prenatal
17.8.6.6.
Rest of
Middle East & Africa Immunodeficiency Therapeutics Market Revenue (US$ Mn)
and Forecasts, By End Users
17.8.6.6.1.
Hospitals
and Clinics
17.8.6.6.2.
Specialized
Clinics
17.8.6.6.3.
Research
Centers
17.8.6.6.4.
Others
17.9. Key Segment for Channeling Investments
17.9.1. By Country
17.9.2. By Therapy Type
17.9.3. By Route of Administration
17.9.4. By Disorder Type
17.9.5. By Demography
17.9.6. By Test Type
17.9.7. By End Users
18. Latin America Immunodeficiency Therapeutics
Market Analysis and Forecasts, 2022 – 2030
18.1. Overview
18.1.1. Latin America Immunodeficiency Therapeutics
Market Revenue (US$ Mn)
18.2. Latin America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Therapy Type
18.2.1. Gene Therapy
18.2.2. Immunoglobulin Replacement Therapy
18.2.3. Antibiotics Therapy
18.2.4. Stem Cell Transportation
18.2.5. Others
18.3. Latin America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
18.3.1. Intravenous
18.3.2. Subcutaneous
18.4. Latin America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Disorder Type
18.4.1. Primary
18.4.1.1.
Common
Variable Immunodeficiency (CVID)
18.4.1.2.
Severe
Combined Immunodeficiency (SCID) (Alymphocytosis)
18.4.1.3.
Chronic
Granulomatous Disease (CGD)
18.4.1.4.
Others
18.4.2. Secondary
18.4.2.1.
AIDS
18.4.2.2.
Cancer
18.4.2.3.
Hepatitis
18.4.2.4.
Others
18.5. Latin America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Demography
18.5.1. Adults
18.5.2. Kids
18.6. Latin America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Test Type
18.6.1. Blood
18.6.2. Prenatal
18.7. Latin America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By End Users
18.7.1. Hospitals and Clinics
18.7.2. Specialized Clinics
18.7.3. Research Centers
18.7.4. Others
18.8. Latin America Immunodeficiency Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
18.8.1. Brazil
18.8.1.1.
Brazil
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
18.8.1.1.1.
Gene
Therapy
18.8.1.1.2.
Immunoglobulin
Replacement Therapy
18.8.1.1.3.
Antibiotics
Therapy
18.8.1.1.4.
Stem
Cell Transportation
18.8.1.1.5.
Others
18.8.1.2.
Brazil
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
18.8.1.2.1.
Intravenous
18.8.1.2.2.
Subcutaneous
18.8.1.3.
Brazil
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
18.8.1.3.1.
Primary
18.8.1.3.1.1. Common Variable Immunodeficiency (CVID)
18.8.1.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
18.8.1.3.1.3. Chronic Granulomatous Disease (CGD)
18.8.1.3.1.4. Others
18.8.1.3.2.
Secondary
18.8.1.3.2.1. AIDS
18.8.1.3.2.2. Cancer
18.8.1.3.2.3. Hepatitis
18.8.1.3.2.4. Others
18.8.1.4.
Brazil
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
18.8.1.4.1.
Adults
18.8.1.4.2.
Kids
18.8.1.5.
Brazil
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
18.8.1.5.1.
Blood
18.8.1.5.2.
Prenatal
18.8.1.6.
Brazil
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
18.8.1.6.1.
Hospitals
and Clinics
18.8.1.6.2.
Specialized
Clinics
18.8.1.6.3.
Research
Centers
18.8.1.6.4.
Others
18.8.2. Argentina
18.8.2.1.
Argentina
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
18.8.2.1.1.
Gene
Therapy
18.8.2.1.2.
Immunoglobulin
Replacement Therapy
18.8.2.1.3.
Antibiotics
Therapy
18.8.2.1.4.
Stem
Cell Transportation
18.8.2.1.5.
Others
18.8.2.2.
Argentina
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
18.8.2.2.1.
Intravenous
18.8.2.2.2.
Subcutaneous
18.8.2.3.
Argentina
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disorder Type
18.8.2.3.1.
Primary
18.8.2.3.1.1. Common Variable Immunodeficiency (CVID)
18.8.2.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
18.8.2.3.1.3. Chronic Granulomatous Disease (CGD)
18.8.2.3.1.4. Others
18.8.2.3.2.
Secondary
18.8.2.3.2.1. AIDS
18.8.2.3.2.2. Cancer
18.8.2.3.2.3. Hepatitis
18.8.2.3.2.4. Others
18.8.2.4.
Argentina
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Demography
18.8.2.4.1.
Adults
18.8.2.4.2.
Kids
18.8.2.5.
Argentina
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By Test
Type
18.8.2.5.1.
Blood
18.8.2.5.2.
Prenatal
18.8.2.6.
Argentina
Immunodeficiency Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
Users
18.8.2.6.1.
Hospitals
and Clinics
18.8.2.6.2.
Specialized
Clinics
18.8.2.6.3.
Research
Centers
18.8.2.6.4.
Others
18.8.3. Rest of Latin America
18.8.3.1.
Rest of
Latin America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
18.8.3.1.1.
Gene
Therapy
18.8.3.1.2.
Immunoglobulin
Replacement Therapy
18.8.3.1.3.
Antibiotics
Therapy
18.8.3.1.4.
Stem
Cell Transportation
18.8.3.1.5.
Others
18.8.3.2.
Rest of
Latin America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
18.8.3.2.1.
Intravenous
18.8.3.2.2.
Subcutaneous
18.8.3.3.
Rest of
Latin America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Disorder Type
18.8.3.3.1.
Primary
18.8.3.3.1.1. Common Variable Immunodeficiency (CVID)
18.8.3.3.1.2. Severe Combined Immunodeficiency (SCID)
(Alymphocytosis)
18.8.3.3.1.3. Chronic Granulomatous Disease (CGD)
18.8.3.3.1.4. Others
18.8.3.3.2.
Secondary
18.8.3.3.2.1. AIDS
18.8.3.3.2.2. Cancer
18.8.3.3.2.3. Hepatitis
18.8.3.3.2.4. Others
18.8.3.4.
Rest of
Latin America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Demography
18.8.3.4.1.
Adults
18.8.3.4.2.
Kids
18.8.3.5.
Rest of
Latin America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Test Type
18.8.3.5.1.
Blood
18.8.3.5.2.
Prenatal
18.8.3.6.
Rest of
Latin America Immunodeficiency Therapeutics Market Revenue (US$ Mn) and
Forecasts, By End Users
18.8.3.6.1.
Hospitals
and Clinics
18.8.3.6.2.
Specialized
Clinics
18.8.3.6.3.
Research
Centers
18.8.3.6.4.
Others
18.9. Key Segment for Channeling Investments
18.9.1. By Country
18.9.2. By Therapy Type
18.9.3. By Route of Administration
18.9.4. By Disorder Type
18.9.5. By Demography
18.9.6. By Test Type
18.9.7. By End Users
19. Competitive Benchmarking
19.1. Brand Benchmarking
19.2. Market Share Analysis, 2021
19.3. Global Presence and Growth Strategies
19.3.1. Mergers and Acquisitions
19.3.2. Product Launches
19.3.3. Investments Trends
19.3.4. R&D Initiatives
20. Player Profiles
20.1. ADMA Biologics
20.1.1. Company Details
20.1.2. Company Overview
20.1.3. Product Offerings
20.1.4. Key Developments
20.1.5. Financial Analysis
20.1.6. SWOT Analysis
20.1.7. Business Strategies
20.2. Baxter
20.2.1. Company Details
20.2.2. Company Overview
20.2.3. Product Offerings
20.2.4. Key Developments
20.2.5. Financial Analysis
20.2.6. SWOT Analysis
20.2.7. Business Strategies
20.3. CSL
20.3.1. Company Details
20.3.2. Company Overview
20.3.3. Product Offerings
20.3.4. Key Developments
20.3.5. Financial Analysis
20.3.6. SWOT Analysis
20.3.7. Business Strategies
20.4. Grifols, S.A.
20.4.1. Company Details
20.4.2. Company Overview
20.4.3. Product Offerings
20.4.4. Key Developments
20.4.5. Financial Analysis
20.4.6. SWOT Analysis
20.4.7. Business Strategies
20.5. GSK Group of Companies
20.5.1. Company Details
20.5.2. Company Overview
20.5.3. Product Offerings
20.5.4. Key Developments
20.5.5. Financial Analysis
20.5.6. SWOT Analysis
20.5.7. Business Strategies
20.6. Lupin Pharmaceuticals Inc.
20.6.1. Company Details
20.6.2. Company Overview
20.6.3. Product Offerings
20.6.4. Key Developments
20.6.5. Financial Analysis
20.6.6. SWOT Analysis
20.6.7. Business Strategies
20.7. Novartis AG
20.7.1. Company Details
20.7.2. Company Overview
20.7.3. Product Offerings
20.7.4. Key Developments
20.7.5. Financial Analysis
20.7.6. SWOT Analysis
20.7.7. Business Strategies
20.8. Octapharma AG
20.8.1. Company Details
20.8.2. Company Overview
20.8.3. Product Offerings
20.8.4. Key Developments
20.8.5. Financial Analysis
20.8.6. SWOT Analysis
20.8.7. Business Strategies
20.9. Takeda Pharmaceutical Company Limited
20.9.1. Company Details
20.9.2. Company Overview
20.9.3. Product Offerings
20.9.4. Key Developments
20.9.5. Financial Analysis
20.9.6. SWOT Analysis
20.9.7. Business Strategies
20.10. X4 Pharmaceuticals, Inc
20.10.1. Company Details
20.10.2. Company Overview
20.10.3. Product Offerings
20.10.4. Key Developments
20.10.5. Financial Analysis
20.10.6. SWOT Analysis
20.10.7. Business Strategies
20.11. Other Market Participants
21. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.